JP7039470B2 - がんの治療において治療薬として使用するための、モノカルボン酸トランスポーター４（ｍｃｔ４）アンチセンスオリゴヌクレオチド（ａｓｏ）阻害剤 - Google Patents

がんの治療において治療薬として使用するための、モノカルボン酸トランスポーター４（ｍｃｔ４）アンチセンスオリゴヌクレオチド（ａｓｏ）阻害剤 Download PDF

Info

Publication number
JP7039470B2
JP7039470B2 JP2018527863A JP2018527863A JP7039470B2 JP 7039470 B2 JP7039470 B2 JP 7039470B2 JP 2018527863 A JP2018527863 A JP 2018527863A JP 2018527863 A JP2018527863 A JP 2018527863A JP 7039470 B2 JP7039470 B2 JP 7039470B2
Authority
JP
Japan
Prior art keywords
seq
aso
cancer
mct4
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018527863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500334A5 (enExample
JP2019500334A (ja
Inventor
ワン，ユージュオ
イウ チュアン チョイ，スティーブン
Original Assignee
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア filed Critical ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア
Publication of JP2019500334A publication Critical patent/JP2019500334A/ja
Publication of JP2019500334A5 publication Critical patent/JP2019500334A5/ja
Application granted granted Critical
Publication of JP7039470B2 publication Critical patent/JP7039470B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2018527863A 2015-11-30 2016-11-30 がんの治療において治療薬として使用するための、モノカルボン酸トランスポーター４（ｍｃｔ４）アンチセンスオリゴヌクレオチド（ａｓｏ）阻害剤 Active JP7039470B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562260837P 2015-11-30 2015-11-30
US62/260,837 2015-11-30
PCT/CA2016/000296 WO2017091885A1 (en) 2015-11-30 2016-11-30 Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2019500334A JP2019500334A (ja) 2019-01-10
JP2019500334A5 JP2019500334A5 (enExample) 2019-12-26
JP7039470B2 true JP7039470B2 (ja) 2022-03-22

Family

ID=58795956

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018527863A Active JP7039470B2 (ja) 2015-11-30 2016-11-30 がんの治療において治療薬として使用するための、モノカルボン酸トランスポーター４（ｍｃｔ４）アンチセンスオリゴヌクレオチド（ａｓｏ）阻害剤

Country Status (9)

Country Link
US (2) US10889814B2 (enExample)
EP (1) EP3384028B1 (enExample)
JP (1) JP7039470B2 (enExample)
CN (1) CN108603194A (enExample)
AU (1) AU2016363683B2 (enExample)
CA (1) CA3006827A1 (enExample)
ES (1) ES2893294T3 (enExample)
MX (1) MX2018006527A (enExample)
WO (1) WO2017091885A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017091885A1 (en) 2015-11-30 2017-06-08 The University Of British Columbia Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer
MX2019001389A (es) 2019-01-31 2020-02-20 Atso Corp Affairs S A De C V Oligonucleotidos antisentido de las glutation s transferasa para el tratamiento del cancer.
EP3999117A4 (en) * 2019-07-12 2023-07-26 Duke University NANOPARTICLE SYSTEMS FOR TARGETED CRISPR/CAS13 DELIVERY AND METHODS OF USE THEREOF
CN113197903B (zh) * 2021-05-08 2022-01-07 江南大学 聚普瑞锌在制备用于治疗去势抵抗性前列腺癌药物中的应用
WO2022250466A1 (ko) * 2021-05-27 2022-12-01 사회복지법인 삼성생명공익재단 전립선암의 엔잘루타미드 저항성 억제용 약학 조성물 및 엔잘루타미드 저항성을 가지는 전립선암 치료용 약학 조성물
CN113717971B (zh) * 2021-08-10 2025-03-28 南通大学 PGK1靶向siRNA干扰库及其应用
CN114324870A (zh) * 2021-12-22 2022-04-12 中国人民解放军空军军医大学 靶向髓系细胞乳酸转运信号的肺癌生物标志物和检测试剂盒
CN114246829B (zh) * 2021-12-31 2023-03-24 北京大学 一种反义核酸药物的包载方法、由该方法制备得到的药物制剂及其在肝癌治疗中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503309A (ja) 1999-02-26 2003-01-28 ザ ユニバーシティ オブ ブリティッシュ コロンビア Ｔｒｐｍ−２アンチセンス療法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19832763A1 (de) 1997-07-21 1999-03-18 Schuster Christoph Kraftfahrzeug mit einem verschließbaren Fahrerraum
US20030059781A1 (en) * 2000-03-21 2003-03-27 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer
US6637473B2 (en) 2000-10-30 2003-10-28 Robodesign International, Inc. Automated storage and retrieval device and method
NZ538841A (en) 2002-10-02 2006-10-27 Univ British Columbia Compositions for reducing hsp27 for the treatment of prostate and other cancers
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US20050255114A1 (en) * 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
GB2407837B (en) 2003-11-04 2007-07-11 Corus Uk Ltd Traffic control barriers
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
US20100209914A1 (en) * 2007-05-25 2010-08-19 Ore Pharmaceuticals , Inc. Methods, systems, and kits for evaluating multiple sclerosis
US10570457B2 (en) 2014-09-26 2020-02-25 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
WO2017091885A1 (en) 2015-11-30 2017-06-08 The University Of British Columbia Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503309A (ja) 1999-02-26 2003-01-28 ザ ユニバーシティ オブ ブリティッシュ コロンビア Ｔｒｐｍ−２アンチセンス療法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Science，2011年，vol.102, no.5，p.1007-1013

Also Published As

Publication number Publication date
ES2893294T3 (es) 2022-02-08
MX2018006527A (es) 2018-11-29
AU2016363683A1 (en) 2018-07-12
EP3384028A4 (en) 2019-05-01
WO2017091885A8 (en) 2018-06-07
US11466273B2 (en) 2022-10-11
CN108603194A (zh) 2018-09-28
AU2016363683B2 (en) 2023-04-27
EP3384028A1 (en) 2018-10-10
EP3384028B1 (en) 2021-06-30
US20190010492A1 (en) 2019-01-10
US10889814B2 (en) 2021-01-12
WO2017091885A1 (en) 2017-06-08
CA3006827A1 (en) 2017-06-08
JP2019500334A (ja) 2019-01-10
US20210395733A1 (en) 2021-12-23
BR112018011045A2 (pt) 2018-11-21

Similar Documents

Publication Publication Date Title
US11466273B2 (en) Monocarboxylate transporter 4 (MCT4) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer
Yang et al. A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization
US11723947B2 (en) Anti-senescence compounds and uses thereof
KR20160143775A (ko) iNOS-억제 조성물들 및 이들의 유방암 치료제로서의 용도
EP3807410A1 (en) Combination therapies comprising c/ebp alpha sarna
Choi et al. Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer
WO2018129622A1 (en) Dual targeting antisense oligonucleotides for use as apoptotic inhibitors for the treatment of cancer
Lee et al. Feedback amplification of senolysis using caspase-3-cleavable peptide-doxorubicin conjugate and 2DG
Qin et al. Combination of dendrobium mixture and metformin curbs the development and progression of diabetic cardiomyopathy by targeting the lncRNA NEAT1
TW201517918A (zh) 癌症放射治療的增敏劑
CN110592222B (zh) Triml1作为肝癌的分子标记物的应用
CN113440511B (zh) Hotair-prc2阻断剂及其复合制剂在制备治疗子宫内膜癌药物中的用途
KR101191958B1 (ko) Ｔｌｅ1 억제제를 유효성분으로 함유하는 활액막 육종 예방 및 치료용 약학적 조성물
WO2019107487A1 (ja) マイクロｒｎａ及びその誘導体を有効成分とする医薬組成物
WO2018160699A1 (en) Biomarkers for diagnosis, prediction and/or prognosis of pancreatic cancer and uses thereof
US20250205271A1 (en) Micrornas for inhibiting the expression of trf2 in tumors
KR102212699B1 (ko) 유방암 예방 또는 치료용 조성물
BR112018011045B1 (pt) Oligonucleotídeo anti-sentido (aso), uso do mesmo na fabricação de um medicamento para o tratamento de câncer e composição farmacêutica
CN119158017A (zh) Trim34抑制剂在制备肿瘤治疗药物中的用途
Zheng et al. Thymoquinone Enhances the Antitumor Activity of Apatinib Against Gastrointestinal Tumors Through the STAT3 Pathway
JP2021031389A (ja) 放射線治療効果増強剤
CN108348539A (zh) 用于治疗肿瘤的方法
JP5976922B2 (ja) 二本鎖核酸分子、ｄｎａ、ベクター、癌細胞増殖抑制剤、及び医薬
JP2023011959A (ja) 医薬組成物
Leonetti et al. 334 POSTER Combination of c-myc and bci-2 antisense oligonucleotides with docetaxel is highly effective in vitro and in vivo on hormone-refractory prostate cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220215

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220309

R150 Certificate of patent or registration of utility model

Ref document number: 7039470

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250